Hepatitis b surface antigen Seroclearance: Relationship to hepatitis b e-Antigen Seroclearance and hepatitis b e-Antigen-negative hepatitis

American Journal of Gastroenterology

Volumn 109, Issue 11, 2014, Pages 1764-1770

  Fung, James ^a,b,c   Wong, Danny Ka Ho ^a,b   Seto, Wai Kay ^a,b   Kopaniszen, Maggie ^a   Lai, Ching Lung ^a,b   Yuen, Man Fung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; TELBIVUDINE; THYMOSIN ALPHA1; VIRUS DNA; VIRUS VACCINE; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; TREATMENT INDICATION; VIRAL CLEARANCE; ADOLESCENT; BLOOD; HEPATITIS B, CHRONIC; HONG KONG; IMMUNOLOGY; MIDDLE AGED; SEROLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; MALE; MIDDLE AGED; SEROLOGIC TESTS;

EID: 84909962198     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.301     Document Type: Article

References (25)

1. Lai CL , Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147: 58-61
2. Sorrell MF , Belongia EA , Costa J et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009; 49: S4-S12.
3. de Franchis R , Meucci G , Vecchi M et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191-4.
4. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14: 381-96.
5. Fung J , Lai CL , Tanaka Y et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009; 104: 1940-6. quiz 1947
6. Ahn SH , Park YN , Park JY et al. Long-Term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance . J Hepatol 2005; 42: 188-94.
7. Chu CM , Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-Term follow-up. Hepatology 2007; 45: 1187-92.
8. Gish RG , Chang TT , Lai CL et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17: 16-22.
9. Fung J , Lai CL , Yuen MF. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Rev Anti Infect Ther 2010; 8: 717-26.
10. Fung J , Lai CL , Young J et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011; 106: 1766-73.
11. Seto WK , Liu K , Wong DK et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013; 59: 709-16.
12. Seto WK , Lam YF , Fung J et al. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after five years of entecavir treatment. J Gastroenterol Hepatol 2013; 29: 1028-34.
13. Yuen MF , Wong DK , Fung J et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.
14. Lok AS , Heathcote EJ , Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-53.
15. Liaw YF , Leung N , Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472-89.
16. Liaw YF , Leung N , Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 3: 263-83.
17. Fung J , Lai CL , Young J et al. Stability of hepatitis B surface antigen over time: implications for studies using stored sera. J Medical Virol 2011; 83: 1900-4.
18. Chu CM , Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007; 14: 147-52.
19. Wong DK , Seto WK , Fung J et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of diff erent potency. Clin Gastroenterol Hepatol 2013; 11: 1004-10. e1001
20. Tseng TC , Liu CJ , Su TH et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-25. e511-512
21. Seto WK , Wong DK , Fung J et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012; 56: 812-9.
22. Fung J , Seto WK , Wong DK et al. Hepatitis B surface antigen levels after hepatitis B e-Antigen seroclearance: a longitudinal follow-up study. Liver Int 2014; advance online publication, 20 May 2014; doi:10.1111/liv.12596.
23. Marcellin P , Heathcote EJ , Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
24. Heathcote EJ , Marcellin P , Buti M et al. Th ree-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-43.
25. Zoutendijk R , Hansen BE , van Vuuren AJ et al. Serum HBsAg decline during long-Term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011; 204: 415-8.